Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label phase 3 safety study of oral linaclotide in children with functional constipation or IBS-C
MOH_2021-10-02_009862Phase 3Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of linaclotide in functional constipation (FC) and irritable bowel syndrome (IBS) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Long-term safety of linaclotide. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
linaclotide
03
Conditions
functional constipation (FC)irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on MOH_2021-10-02_009862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-02_009862.